AHA 2018 Icosapent ethyl resulted in a 25% risk reduction of important ischemic events and also reduced CV death in well-treated patients with elevated triglyceride levels at risk of CV events in the REDUCE-IT trial.
AHA 2018 Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.
A Dutch observational study considered idarucizumab usage inappropriate in 28% of patients. Effective hemostasis was achieved in 67% of patients presenting with bleeding and is associated with lower mortality.
AHA 2018 The American Heart Association (AHA) and the American College of Cardiology (ACC) updated the 2018 cholesterol guidelines. A summary of key recommendations concerning cholesterol management in de prevention of CVD.
AHA 2018 In Japanese patients aged ≥75 years with elevated LDL-c levels, ezetimibe results in prevention of atherosclerotic CV events, as shown in the EWTOPIA75 randomized trial.
AHA 2018 The Federal physical activity guidance stresses the importance and feasibility of incorporating more physical activity in daily life for all ages, and highlights all preventive benefits of physical activity.
AHA 2018 The VITAL trial tested the effect of vitamin D and/or omega-3 supplementation on CVD and cancer outcomes in a large primary prevention cohort, and found few benefits of either product.
AHA 2018 Yoga-CaRe is safe, feasible and significantly improves quality of life and return to pre-infarct daily activities. The per-protocol analysis suggests that yoga does lower CV events in adherent patients.
AHA 2018 In the randomized REDUCE-IT trial, daily treatment with icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowered CV events in primary and secondary prevention of hypertriglyceridemic patients.
AHA 2018 The updated cholesterol guidelines help physicians to personalize treatment based on risk assessment, and now include CAC measurement to guide treatment decisions in certain patients.
In an observational study, antihypertensive treatment was not associated with reduced mortality or rates of CVD in low-risk patients with mild hypertension.
In this randomized trial, the long-term intensive PREDIMED-Plus lifestyle intervention resulted in weight loss and reduced CV risk in overweight/obese adults with metabolic syndrome, compared to standard care.